Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio di 48 mesi per valutare l'efficacia a lungo termine di Elocta sulla salute delle articolazioni (A-MORE)

18 settembre 2026 aggiornato da: Swedish Orphan Biovitrum

Uno studio osservazionale multicentrico di 48 mesi per valutare l'efficacia a lungo termine di Elocta sulla salute delle articolazioni

This is a 48-month observational, prospective, multicentre study. The overall aim of the study is to evaluate the long-term effectiveness of Elocta treatment on joint health in patients treated prophylactically with Elocta in a real-world setting.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Haemophilia A is a rare genetic disorder estimated to occur in one out of 10,000 live births, characterized by a deficiency in coagulation factor VIII causing impaired haemostasis and prolonged bleeding episodes. Moderate haemophilia, defined as < 5%, and severe haemophilia, defined as < 1% of normal factor VIII activity result in frequent and spontaneous bleeds into muscles and joints, commonly the elbows, knees, and ankles. Bleeding into joints can cause acute pain and swelling and can result in reduced joint range of motion, long-term cartilage damage and debilitating haemophilic arthropathy. Early use of prophylaxis with factor VIII replacement is recommended following diagnosis of haemophilia A to maintain joint health and prevent joint destruction. However, despite the use of prophylaxis many patients still experience joint bleeds which may lead to joint deterioration over time. The risk of joint bleeds increases with the amount of time spent below certain FVIII trough levels, e.g. 1, 3 or 5 IU/dL. Thus, there is probably a relation between the intensity of the prophylactic treatment regimen and joint health. Elocta is an extended half-life rFVIII product (EHL rFVIII), with a slower clearance as compared to conventional FVIII products. Treatment with Elocta will therefore provide the treater with a greater flexibility for individualizing prophylaxis as compared to conventional FVIII. Higher trough levels can be reached with Elocta without increasing factor usage or injection frequency. The treater can instead choose to reduce the injection frequency or the factor consumption without lowering trough levels.

Patients may limit their physical activities due to fear of bleeding if they are unaware of their current FVIII level. Patient apps and wearables are now available which allow patients to view their predicted FVIII levels, and capture health-related data (such as bleedings, pain, well-being, physical activity levels etc.). This data can be shared with the treating physician supporting the planning to individualize the patient's factor treatment based on current lifestyle, health status and physical activity levels. Florio, a certified medical device used as part of routine clinical practice, is such an app, and the data output and patient feedback on their activity levels and sense of protection while using Florio will be analysed as exploratory objectives in this study.

The main purpose of this study is to evaluate the effectiveness of Elocta on joint health over a long observation period (48 months). The study will also explore the influence on long term joint health of different Elocta prophylaxis regimens leading to different trough levels and if the extent of patients' physical activity levels can be associated with predicted FVIII levels.

Tipo di studio

Osservativo

Iscrizione (Effettivo)

427

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Riyadh, Arabia Saudita
        • Dr Suliman Al Habib Hospital Riyadh
      • Riyadh, Arabia Saudita
        • King Faisal Specialised Hospital, KFSH Riyadh, Children
      • Riyadh, Arabia Saudita
        • King Faisal Specialist Hospital KFSH, Adults
      • Riyadh, Arabia Saudita
        • Riyadh Military Hospital (P.S.M.C)
      • Brno, Cechia
        • University Hospital Brno
      • Ostrava, Cechia
        • University Hospital Ostrava
      • Prague, Cechia
        • Dept. of Pediatric Haematology and Oncology, University Hospital Motol
      • Tallinn, Estonia
        • Lastehaigla, Tallinn (Tallinn Children´s Hospital)
      • Tallinn, Estonia
        • The North Estonia Medical Centre Hematoloogiakeskus, Regionalhaigla
      • Helsinki, Finlandia
        • Helsinki University Central Hospital, New Children Hospital
      • Turku, Finlandia
        • Turku University Central Hospital, Paediatric and adolescent haematology and oncology clinic
      • Berlin, Germania
        • Charité-Universitätsmedizin Berlin Campus Virchow Klinikum
      • Bonn, Germania
        • Universitätsklinikum Bonn AöR, Institut für Experimentelle Hämatologie und Transfusionsmedizin
      • Frankfurt, Germania
        • Hämostaseologie/Hämophiliezentrum, Medizinische Klinik 2 Institut für Transfusionsmedizin, Universitätsklinikum
      • Frankfurt, Germania
        • Universitätsklinikum Frankfurt - Klinik für Kinder- und Jugendmedizin
      • Hamburg, Germania
        • Universitätsklinikum Hamburg-Eppendorf (UKE)
      • Hanover, Germania
        • Medizinische Hochschule Hannover
      • Hanover, Germania
        • Werlhof-Institut für Hämostaseologie GmbH
      • Heidelberg, Germania
        • SRH-Klinikum Heidelberg
      • Mörfelden-Walldorf, Germania
        • HZRM Hämöphilie Zentrum Rhein Main
      • München, Germania
        • Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital am Universitätsklinikum München
      • Thessaloniki, Grecia
        • Ippokrateio Hospital Thessaloniki (adult department)
      • Thessaloniki, Grecia
        • Ippokrateio Hospital Thessaloniki (pediatric department)
      • Bari, Italia
        • University of Bari Aldo Moro (Centro Emofilia Policlinico - Pediatria U.O.)
      • Cesena, Italia
        • AUSL Romagna Centro Emofilia U.O.C., Medicina Trasfusionale Dipartimento Patologia, Clinica Ospedale M. Bufalini
      • Genova, Italia
        • Giannina Gaslini Institute
      • Milan, Italia
        • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      • Parma, Italia
        • University Hospital of Parma, AOUP, Haemophilia Center
      • Rome, Italia
        • Uo Malattie Emorragiche e Trombotiche Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Universitá Catolica del Sacro Coure
      • Torino, Italia
        • Azienda Ospedaliera Città della Salute e della Scienza di Torino Regina Margherita
      • Groningen, Olanda
        • University Medical Center Groningen/UMCG
      • Muscat, Oman
        • The Royal Hospital
      • Canterbury, Regno Unito
        • East Kent Hospitals University NHS Foundation Trust, Kent Haemophilia and Thrombosis Centre, Kent and Canterbury Hospital
      • London, Regno Unito
        • Great Ormond Street Hospital, Royal London Hospital for Integrated Medicine
      • Ljubljana, Slovenia
        • University Medical Centre Ljubljana Division of Paediatrics
      • Barcelona, Spagna
        • Sant Johan De Deu
      • Barcelona, Spagna
        • Hospital de la Santa Creu i Sant Pau
      • Barcelona, Spagna
        • Hospital Vall d'Hebron
      • Cruces, Spagna
        • Hospital Universitario Cruces
      • Donostia / San Sebastian, Spagna
        • Hospital Universitario Donostia
      • Murcia, Spagna
        • Hospital Virgen de la Arrixaca
      • Málaga, Spagna
        • Hospital Universitario Carlos Haya
      • Navarro, Spagna
        • Complejo Hospitalario de Navarra
      • Oviedo, Spagna
        • Hospital Universitario Central de Asturias (HUCA)
      • Palma de Mallorca, Spagna
        • Hospital Universitario Son Espases
      • Seville, Spagna
        • Hospital Universitario Virgen del Rocío
      • Vigo, Spagna
        • Hospital Alvaro Cunqueiro
      • Gothenburg, Svezia
        • Hematologimottagning Sahlgrenska
      • Malmö, Svezia
        • Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital Malmö
      • Bern, Svizzera
        • Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor Inselspital
      • Lausanne, Svizzera
        • Service et Laboratoire central d'hématologie, Adults
      • Sankt Gallen, Svizzera
        • Zentrum für Labormedizin
      • Zurich, Svizzera
        • Universitätsspital Zürich Klinik für Medizinische Onkologie und Hämatologie

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino
  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Patients diagnosed with haemophilia A regardless of severity, of any gender and age, on factor treatment with Elocta according to usual clinical practice.

Descrizione

Inclusion Criteria:

  • Provided signed and dated informed consent by the patient, or the patient's legally authorized representative(s) for patients under the legal age, before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations
  • Have a diagnosis of haemophilia A
  • At enrolment on prophylactic treatment with Elocta, independent of participation in the study

Exclusion Criteria:

  • Enrolment in another concurrent clinical interventional study, or intake of an Investigational Medicinal Product (IMP), within three months prior to inclusion in this study
  • Presence of factor VIII antibodies (inhibitors) (≥0.60 Bethesda Unit [BU]/mL) at the latest available inhibitor test

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Hemophilia A patients

All patients diagnosed with haemophilia A regardless of severity, on factor treatment with Elocta according to usual clinical practice.

Extended half-life factor VIII product

Altri nomi:
  • efmoroctocog alfa
  • ELOCTATO
  • rFVIIIFc

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Joint health: Target joint development
Lasso di tempo: 48 months

Number of target joints

48 months
Joint health: Target joint resolution
Lasso di tempo: 48 months

Number of resolved target joints

48 months
Joint health: Target joint recurrence
Lasso di tempo: 48 months

Number of recurring target joints

48 months
Joint health: Annualised joint bleeding rate (AJBR) for treated bleeds
Lasso di tempo: 48 months

Number of joint bleeding events per year, for treated bleeds

48 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Disease Activity (hypertrophic synovium) and Disease Damage (Cartilage or Bone) scores for elbows, knees and ankles
Lasso di tempo: 48 months

The Haemophilia Early Arthropathy Detection with UltraSound (HEAD-US) protocol will be used. The total score represents the sum of item scores for abnormalities detected. Its values range from 0 (minimum) to 8 (maximum). A higher score indicates a worse outcome.

48 months
Global Gait Score, and/or joint score items for elbows, knees and ankles.
Lasso di tempo: 48 months

The Haemophilia Joint Health Score (HJHS) system will be used. Global Gait Score, and/or Joint score items (swelling, duration of swelling, muscle atrophy, axial alignment, crepitus on motion, flexion loss, instability, extension loss, joint pain, strength, gait) for elbows, knees and ankles.

The minimum score per joint is 0, the maximum score is 20. The overall total joint score (range 0-120) is the sum of the 6 six index joint (elbows, knees and ankles) scores. A higher score indicates a worse outcome.

48 months
Joint and physical evaluation for elbows, knees and ankles.
Lasso di tempo: 48 months

The WFH Physical Examination Score (AKA Gilbert Score) will be used. Joint evaluation (pain, bleeding, physical examination and radiologic evaluation) and physical evaluation (swelling, muscle atrophy, axial deformity, crepitus on motion, range of motion, flexion contracture, and instability). A higher score indicates a worse outcome.

48 months

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Effectiveness of Elocta: Annualised bleeding rate (ABR) for treated bleeds
Lasso di tempo: 48 months

Number of bleeding events per year, for treated bleeds

48 months
Effectiveness of Elocta: Annualised bleeding rate (ABR) for all bleeds
Lasso di tempo: 48 months

Number of bleeding events per year, for all bleeds

48 months
Effectiveness of Elocta: Occurrence of zero (0) joint bleeds
Lasso di tempo: 48 months

Percentage (%) of study population with zero (0) joint bleeds

48 months
Effectiveness of Elocta: Work productivity and impairment
Lasso di tempo: 48 months

Assessed by WPAI-SHP questionnaire

48 months
Effectiveness of Elocta: Quality of Life
Lasso di tempo: 48 months

Assessed by Haemo-QoL/Haem-A-QoL questionnaire

48 months
Effectiveness of Elocta: Physical activity level
Lasso di tempo: 48 months

Assessed by the Saltin-Grimby scale

48 months
Effectiveness of Elocta: Quality of Life
Lasso di tempo: 48 months

Assessed by EQ-5D-5L/EQ-5D-Y questionnaire

48 months
Effectiveness of Elocta: Severity of joint health
Lasso di tempo: 48 months

Assessed by Patient Global Impression of Severity of Joint Health questionnaire

48 months
Effectiveness of Elocta: FVIII plasma levels
Lasso di tempo: 48 months

Percentage (%) of FVIII plasma level

48 months
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Lasso di tempo: 48 months

Assessed by medication dose

48 months
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Lasso di tempo: 48 months

Assessed by total number of exposure days per medication

48 months
Usage of Elocta: Annualised injection frequency per subject
Lasso di tempo: 48 months

Assessed by prescription

48 months
Usage of Elocta: Annualised factor consumption per subject
Lasso di tempo: 48 months

Assessed by prescription [IU/kg]

48 months
Usage of Elocta: Adherence
Lasso di tempo: 48 months

Investigator assessed (Percentage (%))

48 months
Exploratory Objective
Lasso di tempo: 48 months

Influence of different Elocta prophylaxis regimens on long term joint health

48 months
Exploratory Objective: Impact of florio HAEMO on patients' sense of protection and their activity level
Lasso di tempo: 48 months

Results from questionnaire on impact of florio HAEMO tools on patients' sense of protection and their activity level

48 months
Exploratory Objective: Explore adherence to prescribed treatment regimen
Lasso di tempo: 48 months

florio HAEMO captured treatment adherence scores

48 months
Exploratory Objective: Explore relationship between predicted FVIII levels and physical activity
Lasso di tempo: 48 months

florio HAEMO captured predicted FVIII levels, florio HAEMO captured physical activity (type, duration, heart rate and steps)

48 months
Exploratory Objective: Explore timing of bleeds in relation to predicted FVIII levels and physical activity
Lasso di tempo: 48 months

florio HAEMO captured bleed data (timing, location, cause, treated/untreated), florio HAEMO captured injection data (time, dose), florio HAEMO captured predicted FVIII levels

48 months
Exploratory Objective: Explore the use of Florio to characterise pain and well-being
Lasso di tempo: 48 months

florio HAEMO captured pain data (time, location, cause, intensity), florio HAEMO captured well-being data

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Lasso di tempo: 48 months

Target joint development, resolution and recurrence

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Lasso di tempo: 48 months

Annualised joint bleeding rate (AJBR) for treated bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Lasso di tempo: 48 months

Ultrasound (HEAD-US)

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Lasso di tempo: 48 months

Clinical joint scoring (HJHS)

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Lasso di tempo: 48 months

Annualised bleeding rate (ABR) (based on bleeding episodes assessed according to local practice) for all bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Lasso di tempo: 48 months

Occurrence of zero (0) joint bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Lasso di tempo: 48 months

Quality of Life assessed by Haemo-QoL/Haem-A-QoL

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Lasso di tempo: 48 months

Physical activity level assessed by the Saltin-Grimby scale

48 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Study Physician, Swedish Orphan Biovitrum

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

30 marzo 2020

Completamento primario (Effettivo)

4 maggio 2026

Completamento dello studio (Effettivo)

4 maggio 2026

Date di iscrizione allo studio

Primo inviato

20 febbraio 2020

Primo inviato che soddisfa i criteri di controllo qualità

2 marzo 2020

Primo Inserito (Effettivo)

3 marzo 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

22 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

18 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi